The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Team Science Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world.
We especially encourage applications on prostate cancer disparity research that will help to define the origins of differential outcome for prostate cancer patients in men of under-represented populations, including those focusing on biology or health care access policy. We also seek applications conducting research in VA hospitals where research directly affects veterans with advanced prostate cancer.
The deadline for LOI submission is Friday, March 10, 2023, 3:00pm, Eastern Daylight Time (EDT).
Research proposals in the following topic areas are preferred:
Investigators representing non-profit academic research centers are eligible to apply for PCF Challenge Awards. Investigators from for-profit companies and government-sponsored institutions, with the exception of the VA, are ineligible.
The PCF Challenge Award Team:
• Should be composed of at least 3 investigators capable of providing unique scientific expertise to the solution of this significant problem in prostate cancer research.
• May be assembled from one institution, or several institutions.
• Must embed at least one young investigator as an integral contributor to the team. The young investigator may hold the title of Postdoctoral Fellow, Instructor, Research Associate, Assistant Professor, or equivalent and should be within six- years following completion of a professional degree (MD, DO, PhD, MD-PhD, DSc, ScD, DDM, DDS, DMD, MBBS, or equivalent) or subsequent mentored academic or clinical training program. He or she should not have been granted commitments for more than $300,000 in direct research funding from all sources including institutional funds at the time of this application.
• Applicants who are under-represented in biomedical research are highly encouraged to apply.
